Targeting the Fight Against Cancer

Edison Oncology was founded in 2018 by experienced life science industry veterans to develop and commercialize new therapies targeting the fight against cancer.

Our mission is to develop and commercialize novel cancer therapies to improve the lives of cancer patients and their families.

Developing a Deep Understanding of Cancer Biology

Cancer will affect nearly 35% of people worldwide in their lifetime. In 2020, more than 1.8 million Americans will be diagnosed with cancer1. Cancer is an aggressive and "intelligent" disease that can quickly evolve to resist treatment and evade the human immune system. Left unchecked, cancer ultimately causes death by spreading to critical organs such as the liver, the lungs and the brain. At Edison Oncology, we work with our collaborators to develop a deep understanding of cancer biology in order to identify drug candidates able to overcome treatment resistance and improve survival outcomes and quality of life for cancer patients.

1 Cancer Facts and Figures 2020, American Cancer Society

Our Technology

Targeting Unmet Needs in Cancer Treatment

We are developing a pipeline of unique small-molecule product candidates, each with several “shots on goal” in both orphan and major cancer markets. Our goal is to address unmet medical needs and improve the lives of cancer patients whose tumors harbor mutations known to be targeted by our product candidates.

Our Product Pipeline

We are Dedicated to the Life Sciences Industry

Our team is made up of cancer drug development professionals with years of experience and expertise in the life sciences industry. Together with our academic collaborators and advisors, we share a common dedication to world-class research aimed at commercializing new therapies that improve survival outcomes and quality of life for cancer patients.

Our Leadership Team